Norway· NO-ID_0B57B2A8-3083-46F6-BDC5-5470689CB4A7

Prevymis

A letermovir product containing letermovir, registered in Norway by Merck Sharp & Dohme B.V. (1). The same ATC class is registered in 15 of our 19 countries.

ATC J05AX18

Checked against FEST (Norway) on

Informational only — not a medical device.

SOURCE REGISTER · NOFEST (Norway)normalisedPrevymisATCJ05AX18REGISTER NO.NO-ID_0B57B2A8-3083-4…PACKS LISTED3CHECKEDSeptember 25, 2026

Where it is registered

Letermovir is registered in 15 of 19 countries.

Countries holding a registration under ATC J05AX18 (letermovir), each read from that country’s own register.

  • This record: Norway, from FEST (Norway)
  • 10 of them publish a price we can compare per daily dose

Letermovir · ATC J05AX18

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of letermovir costs, country by country.

Normalised to the WHO defined daily dose (0.48 g), the median price runs from $9.77 in France to $563.69 in Italy — a ×58 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Letermovir · price per daily dose (0.48 g)

USD · FX 28 Sept 2026

  • IT Italy$563.69
  • CH Switzerland$371.41
  • FR France$9.77
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FEST (Norway)
Active substance
Letermovir
Manufacturer
Merck Sharp & Dohme B.V. (1)
Country
Norway (NO)
ATC code
J05AX18
ATC class
Letermovir
Defined daily dose
0.48 g, O
Reimbursed
Not published by this register
Source register
FEST (Norway)
Last checked
September 25, 2026

Packs & prices · 3

1 priced
  • no_merkevare_id
    ID_0B57B2A8-3083-46F6-BDC5-5470689CB4A7
  • no_varenummer
    045552
    28 x 1
    NOK 55506.7
  • gtin
    191778006568

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

222 interactions on record for letermovir.

Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Letermovir · interactions on record

222 records

  • 38 severe
  • 172 moderate
  • 12 minor

Most severe, free to view

  • CisaprideA03FA02severe
  • NaloxegolA06AH03severe
  • EliglustatA16AX10severe
  • CilostazolB01AC23severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Letermovir in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All letermovir products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Prevymis
  • Liechtenstein · Prevymis

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0109b1ee-ca4d-4632-bf21-0e71fc97704e
GET /v1/drugs/0109b1ee-ca4d-4632-bf21-0e71fc97704e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablett, filmdrasjert",
  "source": "fest",
  "status": "A",
  "atc_name": "Letermovir",
  "merkevare_id": "ID_0B57B2A8-3083-46F6-BDC5-5470689CB4A7",
  "name_form_strength": "Prevymis tab 240 mg",
  "prescription_group": "C"
}

See everything about letermovir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.